Oncorus: Shares Look Cheap As First Oncolytic Viral Therapy Enters Clinic
Pixelimage/iStock via Getty Images
Investment Thesis
Since its IPO in October 2020, which raised $87m via the issuance of 5.8m shares at a price of $15, the biotech Oncorus (ONCR) – focused on developing oncolytic virus therapies for solid tumors – has…
